Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

GLP-1 RAs show protective effects against primary open-angle glaucoma and ocular hypertension, surpassing alternative weight ...

While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

“GLP-1 receptor agonist use was not associated with an increased risk of suicidal ideation, self-harm, or suicide” compared ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food ...

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...